Develops targeted alpha-radiation cancer drug candidates and matching imaging diagnostics for patients with neuroendocrine tumors, melanoma and other solid tumors.
10-K for FY2025, filed Mar 16, 2026
Government grants support qualifying project work, with grant revenue tied to eligible expenses as they are incurred. Product buyers submit purchase orders, and product sales are counted when the products ship.
$884K
10-K for FY2025, filed Mar 16, 2026
$884K ↗
Product buyers submit purchase orders, which Perspective accepts before delivering the products specified in the orders.
10-K for FY2025, filed Mar 16, 2026The Company recognizes revenue based on the five-step model for revenue recognition as prescribed by ASU 2014-09, Revenue from Contracts…View ↗
No. It lost $103.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$32.4MView ↗
Shrinking. Revenue fell 91% in 4 years, from $10.1M in FY2021 to $884K in FY2025, about 46% a year.
From seeds to drug development
The earlier business sold cesium-based brachytherapy seeds and related devices for cancer treatment. The latest report describes development of targeted alpha-radiation drug candidates and matching imaging diagnostics for several cancers.
10-K for FY2022, filed Sep 28, 2022 10-K for FY2025, filed Mar 16, 2026The Company’s core product is its Cesium-131 sealed source brachytherapy “seed.” These seeds can be inserted individually or in combination…View ↗
Competes with Bayer, Novartis, Bristol Myers Squibb, Eli Lilly, Sanofi, Lantheus, Telix Pharmaceuticals, Actinium Pharmaceuticals, RadioMedix, AdvanCell, Orano Med, Aktis Oncology, AstraZeneca, Convergent Therapeutics, Johnson & Johnson, ARTBIO, Abdera, ITM, Ipsen, and Pfizer
10-K for FY2025, filed Mar 16, 2026There are also several companies developing alpha-based radiopharmaceuticals for the treatment of cancer, including Bayer, Novartis…View ↗
Loading...